SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination-Reference-Cited by-同舟云学术

SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination

Published:2023-02-28 Issue:5 Volume:58 Page:567-580
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Piñana José Luis^ORCID,Martino Rodrigo^ORCID,Vazquez Lourdes^ORCID,López-Corral Lucia,Pérez Ariadna,Chorão Pedro^ORCID,Avendaño-Pita Alejandro,Pascual María-Jesús,Sánchez-Salinas Andrés,Sanz-Linares Gabriela,Olave María T.,Arroyo Ignacio,Tormo Mar^ORCID,Villalon Lucia,Conesa-Garcia Venancio^ORCID,Gago Beatriz,Terol María-José,Villalba Marta,Garcia-Gutierrez Valentín^ORCID,Cabero Almudena,Hernández-Rivas José Ángel,Ferrer Elena,García-Cadenas Irene^ORCID,Teruel Anabel^ORCID,Navarro David^ORCID,Cedillo Ángel,Sureda Anna,Solano Carlos^ORCID,

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

https://www.nature.com/articles/s41409-023-01946-0.pdf

Reference44 articles.

1. Piñana JL, Martino R, García-García I, Parody R, Morales MD, Benzo G, et al. Risk factors and outcome of COVID-19 in patients with hematological malignancies. Exp Hematol Oncol. 2020;9:21 https://doi.org/10.1186/s40164-020-00177-z

2. Ljungman P, de la Camara R, Mikulska M, Tridello G, Aguado B, Zahrani MA, et al. COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey. Leukemia. 2021;35:2885–94. https://doi.org/10.1038/s41375-021-01302-5

3. Spanjaart AM, Ljungman P, de La Camara R, Tridello G, Ortiz-Maldonado V, Urbano-Ispizua A, et al. Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group. Leukemia. 2021;35:3585–8. https://doi.org/10.1038/s41375-021-01466-0

4. Piñana JL, López-Corral L, Martino R, Montoro J, Vazquez L, Pérez A, et al. SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group. Am J Hematol. 2022;97:30–42. https://doi.org/10.1002/ajh.26385

5. Piñana JL, López-Corral L, Martino R, Vazquez L, Pérez A, Martin-Martin G, et al. SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders. J Hematol Oncol. 2022;15:54 https://doi.org/10.1186/s13045-022-01275-7. Infectious Complications Subcommittee of the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH-TC)

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T cell therapy: A prospective, multicenter, observational study (BMT CTN 2101);2024-01-25

2. Contribution of infection and vaccination to population-level seroprevalence through two COVID waves in Tamil Nadu, India;Scientific Reports;2024-01-24

3. Influence of the Omicron outbreak on allo-HSCT recipients in China: a single-center short-term observational cohort study;Bone Marrow Transplantation;2024-01-11

4. Immunogenicity and Safety of Booster SARS-CoV-2 mRNA Vaccine Dose in Allogeneic Hematopoietic Stem Cell Transplantation Recipients;Transplantation and Cellular Therapy;2023-11

5. Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients;Viruses;2023-10-08